New research published in the September 1, 2014 edition of the British Journal of General Practice shows that invisible blood in urine, called non-visible hematuria, may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians. 
Bladder cancer is the seventh most common cancer in the UK (2011). The disease accounts for 3% of all new cases of cancer. In males, it is the fourth most common cancer…Continue
Added by Editorial Team on August 31, 2014 at 11:30pm — No Comments
Detailed positive results from four ongoing Phase III Odyssey trials of alirocumab (SAR236553/REGN727), which is being developed by Regeneron Pharmaceuticals in collaboration with Sanofi were released today at a Hot Line session at the ESC Congress 2014, being held in Barcelona, Spain, August 30 - September 3, 2014.
Alirocumab is an investigational, fully human,…Continue
Added by Editorial Team on August 31, 2014 at 9:30am — No Comments
Researchers at the at the University of Alberta, Edmonton, Alberta, Canada and the Lawson Health Research Institute, London, Ontario, let by John Lewis, PhD, confirmed that "invadopodia" play a key role in the spread of cancer. The results of their study, which shows that preventing these tentacle-like structures from forming can stop the spread of cancer entirely is published in the August 28, 2014 online edition of Cell Reports. 
In Canada, approximately 2 in 5 will…Continue
Added by Editorial Team on August 29, 2014 at 3:00pm — No Comments
Researchers from the University of Colorado School of Medicine have reported a breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.
In an article published online on August, 29, 2014 in PLOS ONE, researchers from the Charles C. Gates Center for Regenerative…Continue
Added by Editorial Team on August 29, 2014 at 2:00pm — No Comments
The Scottsdale, Arizona, based Ben & Catherine Ivy Foundation, has awarded $10 million in grants for two groundbreaking brain cancer research projects at TGen, the Translational Genomics Research Institute. One of those projects has officially received the final regulatory approval from the University of California, San Francisco, which means patient enrollment for the trial…Continue
Added by Editorial Team on August 28, 2014 at 9:00pm — No Comments
While many researchers and scientists are investigating avenues designed to prevent the onset of a cancer defense mechanism known as autophagy, researchers at Virginia Commonwealth University Massey Cancer Center are leveraging it in a new therapy that causes the process to culminate in cell death rather than survival. Scientists have found that in selective autophagy, the adaptor protein SQSTM1/p62 plays a critical role in recognizing/loading cargo (e.g., malfolded proteins) into…Continue
Added by Editorial Team on August 27, 2014 at 10:00pm — No Comments
A study funded by UCLA's Jonsson Comprehensive Cancer Center and the National Institutes of Health has shown the truth in the saying that knowledge is power. Scientists at UCLA confirmed that when it comes to men making decisions about how to treat their prostate cancer, education plays an important role.
UCLA researchers found that men who are not well educated about their disease have a much more difficult time making treatment decisions, called decisional conflict, a…Continue
Added by Editorial Team on August 26, 2014 at 10:30pm — No Comments
A study published online in Genome Medicine on August 26, 2014, shows that regardless of their stage or type, most cancers appear to share a telltale signature of widespread changes to the so-called epigenome.
In the article, the authors say they have found widespread and distinctive changes in a broad variety of cancers to chemical marks known as methyl groups attached to DNA, which help govern whether genes are turned on or off, and ultimately how the cell…Continue
Added by Editorial Team on August 25, 2014 at 6:30pm — No Comments
Over the past decade, a number of breakthrough treatments have become available for key subtypes of lung cancer. Patients who may benefit from these treatments can be pre-identified by looking for defined genetic abnormalities. For example, patients whose lung cancer is driven by rearrangement of the gene ALK, leading to anaplastic lymphoma kinase or (ALK)-positive non-small cell lung cancer (NSCLC), derive significant benefit from a drug called crizotinib (…Continue
Added by Editorial Team on August 22, 2014 at 8:00pm — No Comments
Women treated for the cancer Hodgkin lymphoma, a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg, will be able to better understand their risks of future infertility after researchers estimated their risk of premature menopause with different treatments.
The findings, set out in the August 19, 2014 edition of the Journal of the National Cancer Institute…Continue
Added by Editorial Team on August 22, 2014 at 7:00pm — No Comments
A new study supported by a research grant from the Ontario Ministry of Health and Long Term Care (MOHLTC) and published first in the July 27, 2014 online edition of the journal Preventive Medicine suggest that women with severe disabilities and multiple chronic conditions are screened for breast cancer less often than women with no disabilities or no chronic conditions.
According to the Sara Guilcher MD, an…Continue
Added by Editorial Team on August 22, 2014 at 5:30pm — No Comments
For the first time an oncogenic somatic mutation at amino acid 918 in the Rearranged During Transfection or RET protein has been identified in Small Cell Lung Cancer or SCLC tumors and enforced expression of this mutation within SCLC cell lines produced increased intracellular signaling and cell growth.
Small Cell Lung Cancer or SCLC is a highly malignant form of lung cancer. The disease represents approximately 15% of all lung cancers and is strongly associated with…Continue
Added by Editorial Team on August 22, 2014 at 4:00pm — No Comments
Researchers from the Norwegian University of Science and Technology (NTNU), Columbia University and MIT, along with researchers from Japan and Germany have found a novel approach to treating cancer: OnabotulinumtoxinA, beter know as BOTOX® (Allergan, Inc).
A study presented in the August 20, 2014 edition of Science Translational Medicine shows that cancer growth could be suppressed by eliminating the signals…Continue
Added by Editorial Team on August 20, 2014 at 9:00pm — No Comments
Researchers from A*STAR's Institute of Molecular and Cell Biology (IMCB), and the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have identified a unique gene that may make it easier to predict both breast cancer relapses and responses to chemotherapy. The newly found biomarker could help physicians classify each breast cancer patient and customise a treatment regimen that is more effective.
Despite advancements in cancer…Continue
Added by Editorial Team on August 19, 2014 at 10:30pm — No Comments
Writing in the Proceedings of the National Academy of Sciences (PNAS) Professors Kim D. Janda and Peter K. Vogt, a research team at The Scripps Research Institute (TSRI) reported that the function of the MYC regulator could be inhibited with small molecule compounds in cell culture and importantly in an experimental cancer animal model.
The MYC protein is a transcriptional factor. This means that it controls gene expression. The MYC protein has been recognized as an…Continue
Added by Editorial Team on August 18, 2014 at 4:00pm — No Comments
Scientists at Washington State University (WSU) have identified a crucial step in DNA repair that may lead to the development of a targeted gene therapy for hereditary diseases such as xeroderma pigmentosum (also known as "children of the moon”) and a common form of colon cancer. Xeroderma pigmentosum, which is diagnosed in early childhood, is based on a genetic defect in the DNA repair system and increases the risk for cancer and other conditions.
The findings are published…Continue
Added by Editorial Team on August 18, 2014 at 12:30pm — No Comments
Retinoic acid, a form of vitamin A, used to treat and help prevent the recurrence of a variety of cancers, may not be effective for some patients. The reason for this resistance was unclear until this week when researchers from Virginia Commonwealth University (VCU) Massey Cancer Center demonstrated that a protein known as AEG-1 blocks the effects of retinoic acid in leukemia and liver cancer. Because AEG-1 is overexpressed in nearly every cancer, these findings could potentially impact…Continue
Added by Editorial Team on August 14, 2014 at 6:00pm — No Comments
Researchers from the Department of Pharmacology & Therapeutics, School of Medicine, Trinity College Dublin in Ireland have discovered that women who had been prescribed aspirin regularly before being diagnosed with breast cancer are less likely to have cancer that spread to the lymph-nodes than women who were not on prescription aspirin. The research also shows that these women are less likely to die from their breast cancer.
The study was funded by the Irish Health…Continue
Added by Editorial Team on August 14, 2014 at 4:00pm — No Comments
According to study results from a study was funded by the U.S. Department of Defense, the Breast Cancer Research Program of the Congressionally Directed Medical Research Programs, and the National Cancer Institute, published in Cancer Research, a journal of the American Association for Cancer Research (AACR), recurrence of hormone-related breast cancer was cut by half in overweight and obese women who regularly used aspirin or other…Continue
Added by Editorial Team on August 14, 2014 at 3:30pm — No Comments
It may seem futuristic, but Imagine being able to match a cancer's genes to the best treatment. That's the promise of CO expression ExtrapolatioN or COXEN, a computer program that looks at a panel of cancer genes in a patient's tumor to predict whether it will respond to chemotherapy. Now a clinical trial recently approved by the National Cancer Institute will open at the University of Colorado Cancer Center and nationally via the Southwest Oncology Group (SWOG) to test the COXEN…Continue
Added by Editorial Team on August 13, 2014 at 7:30pm — No Comments